Details of the Drug
General Information of Drug (ID: DM4CV1E)
Drug Name |
8-Bromo-Adenosine-5'-Monophosphate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
8-Bromoadenosine 5'-monophosphate; 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE; 8-Bromoadenosine 5'-(dihydrogen phosphate); 23567-96-6; 8-Br-AMP; CHEMBL1230617; 8-Bromo-Adenosine Mono Phosphate; 50828-34-7; Poly 8-bromoadenylic acid; 8BR; Poly(8-bra); Poly(8-bromoriboadenylic acid); 8-Bromo-AMP; Adenosine, 8-bromo-, 5'-(dihydrogen phosphate); AC1L518I; SCHEMBL4315602; AC1Q270V; CTK4J3218; 23567-96-6 (monomer); DNPIJKNXFSPNNY-UUOKFMHZSA-N; 8-bromoadenosine-5'-monophosphate; 50828-34-7 (Parent); ZINC13527361; MFCD00056945; BDBM50222467
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 426.12 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||